South Rampart Pharma Achieves Development Milestone and Advances to Phase II of Active NIH Fast-Track STTR Commercialization Award
$1.9 million NIH fast-track STTR grant fuels next stage of clinical program dedicated to the development of a novel non-opioid approach to pain management Lead program SRP-3D (DA) advances in ongoing Phase 1 clinical trial with data expected in the third quarter of 2022 NEW ORLEANS, May…
Comments Off on South Rampart Pharma Achieves Development Milestone and Advances to Phase II of Active NIH Fast-Track STTR Commercialization Award